Literature DB >> 21663505

Myelodysplastic syndromes: the role of the immune system in pathogenesis.

Erica D Warlick1, Jeffrey S Miller.   

Abstract

The myelodysplastic syndromes (MDS) represent a complex spectrum of clonal hematopoietic stem cell disorders manifested by cytopenias, risk of infection, and variable risk of progression to acute myelogenous leukemia. Several theories of MDS pathogenesis exist, with contributions of genetic, epigenetic, apoptotic, differentiation, and cytokine milieu abnormalities. Immune dysregulation has also been implicated in MDS pathogenesis. In some forms of MDS it is evident that immune dysregulation may be a primary pathophysiologic abnormality, while in others the abnormal immune function may represent only a small part of the pathologic puzzle. We review the current literature regarding natural killer (NK) cell, T cell, and myeloid derived suppressor cell abnormalities in the spectrum of MDS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21663505     DOI: 10.3109/10428194.2011.584002

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome.

Authors:  Youshan Zhao; Dong Wu; Chengming Fei; Juan Guo; Shuncheng Gu; Yang Zhu; Feng Xu; Zheng Zhang; Lingyun Wu; Xiao Li; Chunkang Chang
Journal:  Haematologica       Date:  2014-10-31       Impact factor: 9.941

2.  Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function.

Authors:  Dhifaf Sarhan; Jinhua Wang; Upasana Sunil Arvindam; Caroline Hallstrom; Michael R Verneris; Bartosz Grzywacz; Erica Warlick; Bruce R Blazar; Jeffrey S Miller
Journal:  JCI Insight       Date:  2020-03-12

3.  Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: a case report with review of the literature.

Authors:  Ayed A Algarni; Mojtaba Akhtari; Kai Fu
Journal:  Case Rep Hematol       Date:  2012-03-29

4.  IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes.

Authors:  A Pardanani; C Finke; T L Lasho; A Al-Kali; K H Begna; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2011-09-13       Impact factor: 11.528

5.  Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes.

Authors:  Miyoung Kim; Seungwoo Hwang; Kiejung Park; Seon Young Kim; Young Kyung Lee; Dong Soon Lee
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

6.  Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.

Authors:  Suxia Geng; Ruohao Xu; Xin Huang; Minming Li; Chengxin Deng; Peilong Lai; Yulian Wang; Ping Wu; Xiaomei Chen; Jianyu Weng; Xin Du
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

7.  Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Authors:  H Yang; C Bueso-Ramos; C DiNardo; M R Estecio; M Davanlou; Q-R Geng; Z Fang; M Nguyen; S Pierce; Y Wei; S Parmar; J Cortes; H Kantarjian; G Garcia-Manero
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

8.  Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation.

Authors:  Qingtian Li; Jia Zou; Mingjun Wang; Xilai Ding; Iouri Chepelev; Xikun Zhou; Wei Zhao; Gang Wei; Jun Cui; Keji Zhao; Helen Y Wang; Rong-Fu Wang
Journal:  Nat Commun       Date:  2014-12-22       Impact factor: 14.919

9.  Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes.

Authors:  Wen Dong; Tingting Ding; Lei Wu; Xiubao Ren; P K Epling-Burnette; Lili Yang
Journal:  Oncotarget       Date:  2016-05-10

10.  Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-α and IL-32 Levels in Myelodysplastic Syndrome Patients.

Authors:  Salah Aref; Nada Khaled; Abdel Hady Al Gilany; Mohamed Ayed; Tarek Abouzeid; Doaa Attia
Journal:  Asian Pac J Cancer Prev       Date:  2020-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.